Loading…
Bharat Parenterals (BPLPHARMA)₹1,801−6.06%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Bharat Parenterals reported sales of ₹136 Cr, up 109.1% from Sep 2025, and net profit of ₹12.01 Cr. For the year to Mar 2026, sales were ₹345 Cr and net profit −₹26.97 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60.07 | 68.04 | 93.04 | 72.08 | 72.02 | 104 | 116 | 65.06 | 65.04 | 100 | 94.10 | 136 |
| Expenses | 53.16 | 67.16 | 88.24 | 79.25 | 69.17 | 102 | 102 | 64.16 | 63.21 | 100 | 85.21 | 113 |
| Operating Profit | 7.02 | 1.01 | 4.01 | −8.02 | 4.01 | 2.01 | 14.04 | 1.01 | 2.01 | −1.01 | 9.03 | 24.06 |
| OPM % | 10.9% | 1.5% | 4.8% | −11.0% | 5.0% | 2.1% | 12.0% | 1.3% | 2.7% | −0.5% | 9.0% | 16.9% |
| Other Income | 1.01 | 3.01 | 3.01 | 4.01 | 3.01 | 1.99 | 1.01 | 4.01 | 1.01 | 4.01 | 1.01 | 3.01 |
| Interest | 0.99 | 0.99 | 2.99 | 2.99 | 2.99 | 3.99 | 3.99 | 2.99 | 2.99 | 2.99 | 1.99 | 2.99 |
| Depreciation | 2.01 | 4.01 | 9.01 | 9.01 | 9.01 | 9.02 | 9.01 | 9.01 | 8.01 | 9.01 | 9.02 | 9.01 |
| Profit before tax | 4.99 | −1.01 | −4.99 | −15.01 | −5.99 | −7.99 | 2.99 | −6.99 | −7.99 | −8.01 | −2.01 | 13.99 |
| Tax % | 33.0% | 88.0% | 84.9% | 13.9% | 43.0% | 14.0% | 133.9% | 17.9% | 17.0% | −3.0% | 138.0% | 16.0% |
| Net Profit | 3.99 | −2.99 | −8.99 | −17.98 | −7.99 | −8.99 | −0.99 | −8.99 | −9.99 | −7.99 | −3.99 | 12.01 |
| EPS (Rs) | 6.51 | −0.53 | 1.97 | −11.53 | −2.43 | −6.88 | 11.96 | −10.51 | −6.39 | −6.98 | 1.48 | 13.70 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 261 | 340 | 345 | 395 |
| Expenses | 114 | 105 | 124 | 192 | 200 | 180 | 184 | 199 | 235 | 338 | 331 | 362 |
| Operating Profit | 10.03 | 7.02 | 12.03 | 29.09 | 28.07 | 25.05 | 29.10 | 20.06 | 27.09 | 4.01 | 16.05 | 34.09 |
| OPM % | 8.0% | 6.0% | 9.0% | 12.9% | 12.0% | 12.0% | 14.0% | 9.0% | 9.9% | 1.1% | 4.6% | 8.6% |
| Other Income | 4.99 | 8.01 | 7.01 | 13.01 | 11.01 | 8.99 | 6.99 | 12.01 | 5.01 | 10.99 | 10.01 | 9.04 |
| Interest | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 2.99 | 3.99 | 12.99 | 12.98 | 10.96 |
| Depreciation | 4.01 | 6.01 | 6.01 | 6.01 | 6.01 | 6.01 | 7.02 | 6.01 | 9.01 | 35.06 | 34.05 | 35.05 |
| Profit before tax | 9.01 | 7.01 | 12.99 | 35.01 | 32.98 | 26.99 | 27.98 | 24.01 | 19.01 | −33.98 | −21.01 | −4.02 |
| Tax % | 30.9% | 8.0% | 28.9% | 39.0% | 26.0% | 24.9% | 25.0% | 33.0% | 44.0% | 29.0% | 26.9% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −0.28 | 0.21 | −0.52 | 0.28 | −0.04 | −0.68 | 0.28 | — |
| Net Profit | 5.99 | 6.99 | 8.99 | 20.97 | 23.97 | 19.97 | 20.99 | 16.01 | 10.99 | −43.98 | −26.97 | −9.96 |
| EPS (Rs) | 11.28 | 12.05 | 15.94 | 37.14 | 42.20 | 35.67 | 36.54 | 28.52 | 24.98 | −18.37 | −11.91 | 1.81 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.0% | 4.0% | −5.0% | −8.0% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 | 7.00 | 7.00 |
| Reserves | 51.04 | 58.04 | 67.08 | 88.05 | 112 | 138 | 160 | 177 | 191 | 325 | 316 |
| Borrowings | 18.94 | 5.98 | 8.96 | 4.98 | 0.99 | 11.95 | 17.92 | 49.80 | 158 | 180 | 146 |
| Other Liabilities | 44.15 | 40.12 | 50.01 | 60.05 | 67.97 | 43.15 | 42.17 | 118 | 150 | 139 | 146 |
| Total Liabilities | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 505 | 650 | 614 |
| Fixed Assets | 35.11 | 31.08 | 34.08 | 35.12 | 33.09 | 45.13 | 41.09 | 42.12 | 211 | 253 | 256 |
| CWIP | 0.00 | 0.00 | 0.00 | 1.01 | 12.03 | 0.00 | 26.06 | 99.22 | 25.05 | 31.09 | 35.12 |
| Investments | 0.00 | 1.01 | 1.01 | 0.99 | 0.00 | 43.02 | 11.01 | 0.00 | 0.00 | 4.99 | 5.99 |
| Other Assets | 85.01 | 79.04 | 97.95 | 121 | 142 | 111 | 148 | 209 | 268 | 360 | 317 |
| Inventories | 13.99 | 14.99 | 13.99 | 22.99 | 28.97 | 22.01 | 20.99 | 37.99 | 60.98 | 72.02 | 85.01 |
| Trade receivables | 43.99 | 43.94 | 58.99 | 63.94 | 78.91 | 67.94 | 72.89 | 112 | 141 | 172 | 151 |
| Cash & equivalents | 12.97 | 1.99 | 3.99 | 11.97 | 9.97 | 1.99 | 4.99 | 9.97 | 14.96 | 57.88 | 11.98 |
| Total Assets | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 505 | 650 | 614 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −1.99 | 5.99 | 19.99 | 13.99 | 23.99 | −0.99 | 21.98 | −4.99 | −26.98 | 37.98 |
| Cash from investing activity | −2.01 | −7.99 | −9.01 | −13.01 | −42.98 | −6.99 | −78.05 | −105 | −137 | 9.01 |
| Cash from financing activity | −7.99 | 3.99 | −3.99 | −3.01 | 9.99 | 9.01 | 60.93 | 110 | 156 | −47.01 |
| Net cash flow | −10.99 | 1.99 | 6.99 | −0.99 | −7.99 | 1.99 | 3.99 | 0.99 | −7.99 | 0.99 |
| Capex | 2.45 | 8.28 | 8.90 | 15.05 | 0.85 | 39.03 | 91.73 | 105 | 29.13 | 40.05 |
| Free cash flow | −3.99 | −1.99 | 11.97 | 0.00 | 23.93 | −39.88 | −67.79 | −108 | −55.82 | −0.99 |
| CFO / OP % | −8.0% | 73.0% | 107.0% | 87.0% | 123.0% | 15.9% | 150.0% | 18.0% | −444.0% | 305.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 | 198 | 184 | 159 |
| Inventory days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 | 142 | 132 | 162 |
| Days payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 136 | 137 | 136 | 122 |
| Cash conversion cycle | 20 | 44 | 106 | 81 | 92 | 110 | 117 | 151 | 201 | 179 | 198 |
| Working capital days | 7 | 63 | 77 | 72 | 88 | 105 | 147 | 90 | 80 | 75 | 142 |
| ROCE % | — | 10.9% | 17.9% | 38.9% | 30.9% | 19.9% | 16.9% | 10.9% | 6.9% | −4.0% | −2.0% |
For the Sep 2026 quarter, Bharat Parenterals reported sales of ₹136 Cr, up 109.1% year on year and net profit of ₹12.01 Cr. The operating margin was 16.9%.
Bharat Parenterals' sales for the year to Mar 2026 were ₹345 Cr; over the last twelve months they were ₹395 Cr.
Net profit for the year to Mar 2026 was −₹26.97 Cr, and −₹9.96 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.81.
Bharat Parenterals reported borrowings of ₹146 Cr at Mar 2026, against cash and equivalents of ₹11.98 Cr.
Cash from operations was ₹37.98 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.99 Cr.